Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors-Reference-Cited by-同舟云学术

Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors

Published:2012-05-31 Issue:11 Volume:55 Page:5291-5310
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ashwell Mark A.¹,Lapierre Jean-Marc¹,Brassard Christopher¹,Bresciano Karen¹,Bull Cathy¹,Cornell-Kennon Susan¹,Eathiraj Sudharshan¹,France Dennis S.¹,Hall Terence¹,Hill Jason¹,Kelleher Eoin¹,Khanapurkar Sampada¹,Kizer Darin¹,Koerner Steffi¹,Link Jeff¹,Liu Yanbin¹,Makhija Sapna¹,Moussa Magdi¹,Namdev Nivedita¹,Nguyen Khanh¹,Nicewonger Robert¹,Palma Rocio¹,Szwaya Jeff¹,Tandon Manish¹,Uppalapati Uma¹,Vensel David¹,Volak Laurie P.¹,Volckova Erika¹,Westlund Neil¹,Wu Hui¹,Yang Rui-Yang¹,Chan Thomas C. K.¹

Affiliation:

1. ArQule Inc., 19 Presidential Way, Woburn, Massachusetts 01801, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm300276x

Reference22 articles.

1. Targeting the phosphoinositide 3-kinase pathway in cancer

2. The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation: A 2009 Update

3. PI3K/Akt signalling pathway and cancer